A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

Inclusion Criteria:

• Participants must be 18 years of age (when signing informed consent form)

• Diagnosis of AD for at least 1 year (defined by the American Academy of DermatologyConsensus Criteria)

• Documented history (within 6 months before screening) of either inadequate responseor inadvisability to topical treatments

• Validated Investigator Global Assessment scale for atopic dermatitis (vIGA-AD) of 3or 4 at baseline visit

• Eczema area and severity index (EASI) score of 12 or higher at baseline

• AD involvement of 10% or more of body surface area (BSA) at baseline

• Able and willing to comply with requested study visits and procedures

• Body weight ≥40 kg and ≤150 kg

Exclusion Criteria:

• Skin co-morbidity that would adversely affect the ability to undertake ADassessments

• Receipt of any vaccine (expect influenza and COVID-19 vaccines) within 3 monthsprior to screening

• Receipt of any pneumococcal vaccine within approximate timeframe of 5 years prior toscreening

• Prior receipt of two or more doses of Pneumovax 23 at any time

• Receipt of any tetanus-, diphtheria-, or pertussis-containing vaccine withinapproximate timeframe of 5 years prior to screening

• Participants for whom administration of the pneumococcal vaccine provided in thisstudy is contraindicated or medically inadvisable, according to local label of thevaccine

• Participants for whom administration of the tetanus, diphtheria, and pertussisvaccine provided in this study is contraindicated or medically inadvisable,according to local label of the vaccine

• Having received any of the specified therapy within the specified timeframe(s) priorto the baseline visit

• Known history of or suspected significant current immunosuppression

• Any malignancies or history of malignancies prior to baseline (excludingnon-melanoma skin cancer excised and cured >5 years prior to baseline)

• History of solid organ or stem cell transplant

• Any active or chronic infection including helminthic infection requiring systemictreatment within 2 weeks prior baseline

• Positive for human immunodeficiency virus (HIV), Hepatitis B or hepatitis C atscreening visit

• Participants with active tuberculosis (TB), latent TB, a history of incompletelytreated TB, suspected extrapulmonary TB infection, or who are at high risk ofcontracting TB

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.